Esperion Therapeutics Inc. share price logo

Esperion Therapeutics Inc.

Quote: ESPR

$3.18

-0.01

(-0.31%)

as on

Bell Icon

This instrument is not available for trading on the INDmoney app on 10 Jul 2026

Esperion Therapeutics Inc. Stock Performance

as on July 13, 2026 at 2:16 pm IST

  • Day's High

    $3.18
    $3.19

    0.31%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.80
    $4.18
    downward going graph

    43.40%

    Downside

    31.29%

    Upside

    downward going graph

Esperion Therapeutics Inc. share price movements today

Previous Close
$3.19
Open
$3.19
Volume
38.7M
Day's Low - High
$3.18 - $3.19
52 Week Low - High
$1.80 - $4.18

Esperion Therapeutics Inc. Historical Returns

1 Month Return
0 %
3 Month Return
0 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Esperion Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Esperion Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$-

EPS (TTM)

0

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0.00

EBITDA

-

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

0.00%

Esperion Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Esperion Therapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Esperion Therapeutics Inc. image
Esperion Therapeutics Inc.
Buy$-NANA0.00%0.00%
United Therapeutics image
United Therapeutics
Buy$23.2B186.99%17.9286.14%0.00%
Viatris image
Viatris
Buy$20.4B29.41%-48.8134.83%2.75%
Haleon PLC Sponsored ADR image
Haleon PLC Sponsored ADR
Buy$38.1BNA18.1065.57%2.25%
Zoetis image
Zoetis
Buy$28.8B-64.53%11.4670.87%3.00%
See all

Analyst Recommendation on Esperion Therapeutics Inc. Stock

Based on 14 analysts

BUY

71.43%

Buy

28.57%

Hold

0.00%

Sell

Based on 14 analysts, 71.43% of analysts recommend a 'BUY' rating for Esperion Therapeutics Inc.. Average target price of $3.19

Esperion Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Esperion Therapeutics Inc..

What analysts predicted

0.31%UPSIDE

Target Price

$3.19

Current Price

$3.18

Analyzed by

14 Analysts

Target

$3.19

Esperion Therapeutics Inc. target price $3.19, a slight upside of 0.31% compared to current price of $3.18. According to 14 analysts rating.

Esperion Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
32
137
73
51
69
64
82
87
168
80
Gross Profit
20
127
58
34
43
33
53
31
140
45
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-56
61
-61
-29
-21
-40
-12
-31
61
-25
Net Profit Margin
-174.71%
44.30%
-83.87%
-57.18%
-30.85%
-62.24%
-15.45%
-35.89%
36.71%
-31.45%

Esperion Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
184
148
227
78
75
116
332
403
Gross Profit
0
0
184
148
225
64
48
73
263
273
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-74
-166
-201
-97
-143
-269
-233
-209
-51
-22
Net Profit Margin
0.00%
0.00%
-109.40%
-65.49%
-63.09%
-343.04%
-309.58%
-179.87%
-15.57%
-5.63%

Global Institutional Holdings in Esperion Therapeutics Inc.

Check out the Institutions with significant holdings in Esperion Therapeutics Inc..

Funds
Holdings
Two Sigma Investments LLC
3.67%
D. E. Shaw & Co LP
2.54%
Bank of America Corp
0.41%
Two Seas Capital LP
4.42%
Orbimed Advisors, LLC
4.10%
See all

Esperion Therapeutics Inc. News & Key Events

  • img

    Today's Timeline - 06 November

    Fri, 00:00 AM

    -

    Analysts maintain Buy ratings for Esperion, citing strong financial performance and growth potential despite insider selling.

    Fri, 06:29 AM

    -

    Esperion reports 69% revenue growth in Q3 2025, driven by U.S. product revenue and strategic marketing initiatives.

Insights on Esperion Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, ESPR stock has moved up by 47.0%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ESPR has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ESPR has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 61.83M → -25.19M (in $), with an average decrease of 140.8% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 168.44M → 80.10M (in $), with an average decrease of 52.5% per quarter

About Esperion Therapeutics Inc.

Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cardiometabolic and rare/orphan disease therapies. It markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels who are at risk of cardiovascular disease and nasal spray, loop diuretic for the treatment of edema associated with congestive heart failure, and hepatic and renal disease. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. NEXLETOL is a first-in-class ACLY inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating LDL receptors. NEXLIZET contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and cholesterol absorption in the intestine. Its Enbumyst is the FDA-approved nasal spray loop diuretic.
OrganisationEsperion Therapeutics Inc.

FAQs

What is Esperion Therapeutics Inc. share price today?

Esperion Therapeutics Inc. share price today is $3.18 as on at the close of the market. Esperion Therapeutics Inc. share today touched a day high of $3.19 and a low of $3.18.

What is the 52 week high and 52 week low for Esperion Therapeutics Inc. share?

Esperion Therapeutics Inc. share touched a 52 week high of $4.18 on and a 52 week low of $1.80 on . Esperion Therapeutics Inc. stock price today i.e. is closed at $3.18,which is 23.83% down from its 52 week high and 76.67% up from its 52 week low.

How to invest in Esperion Therapeutics Inc. Stock (ESPR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Esperion Therapeutics Inc. on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Esperion Therapeutics Inc. Stock (ESPR) from India?

Indian investors can start investing in Esperion Therapeutics Inc. (ESPR) shares with as little as ₹96.292503356934 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹962.93 in Esperion Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Esperion Therapeutics Inc. share’s latest price of $3.18 as on July 13, 2026 at 8:46 am IST, you will get 3.1447 shares of Esperion Therapeutics Inc.. Learn more about fractional shares .